Impact of Pretransplant Comorbidities on Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Hematopoietic SCT for Patients With High-Risk Myelodysplastic Syndrome and AML

Bone Marrow Transplantation - United Kingdom
doi 10.1038/bmt.2009.236
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC


Related search